Cefozopran

• CAT Number: I000502
• CAS Number: 113359-04-9
• Molecular Formula: C19H17N9O5S2
• Molecular Weight: 515.53
• Purity: ≥95%
• Target: Bacterial
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
• InChI: InChI=1S/C19H17N9O5S2/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32)/b24-11-/t12-,17-/m1/s1
• InChIKey: QDUIJCOKQCCXQY-WHJQOFBOSA-N
• SMILES: CO/N=C(/C1=NSC(=N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=C5C=CC=NN5C=C4)C(=O)[O-]

Cefozopran（Cat No.:I000502）is a fourth-generation cephalosporin antibiotic with broad-spectrum efficacy against both Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. It inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins, leading to cell lysis and death. Cefozopran is primarily used in treating severe infections, such as respiratory, urinary tract, and intra-abdominal infections, where resistant strains are a concern. Known for its stability against many beta-lactamases, it remains effective against extended-spectrum beta-lactamase (ESBL)-producing bacteria. Cefozopran’s broad activity makes it valuable in hospital settings for managing complex infections.

Reference

1: Guo WW, Shen Q, Qin YP, Wang Y, Wang L, Miao J, Nan F, Xiang J, Yu Q, Liang
MZ. [Pharmacokinetics of injected cefozopran hydrochloride in healthy
volunteers]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2012 Sep;43(5):711-4. Chinese.
PubMed PMID: 23230745.

2: Kataoka D, Tanaka Y. The combination of aztreonam and cefozopran against
Stenotrophomonas maltophilia. J Infect Chemother. 2004 Feb;10(1):62-4. PubMed
PMID: 14991523.

3: Saito T, Hara M, Shinagawa K, Nawa Y, Nakase K, Takeuchi M, Miyata A, Fukuda
S, Sunami K, Imajoh K, Yano T, Kojima K, Teshima T, Fujii N, Ishimaru F, Ikeda K,
Harada M, Tanimoto M. [Clinical evaluation of cefozopran as treatment for febrile
neutropenia]. Gan To Kagaku Ryoho. 2004 Jan;31(1):61-5. Japanese. PubMed PMID:
14750323.

4: Niinou K, Sato H. [Studies on cefozopran in the pediatric field]. Jpn J
Antibiot. 1994 Nov;47(11):1473-84. Japanese. PubMed PMID: 7853678.